Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

So even a billion-dollar-or-so swing in Zepbound's future sales ... Additionally, Lilly could leverage specialty pharmacies or direct-to-patient models to bypass some PBM restrictions.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Eli Lilly is working on a new drug, orforglipron, an oral tablet taken once daily, with no dietary restrictions ... Eli Lilly's total sales between Mounjaro and Zepbound were slightly under ...